AVI BioPharma appoints interim president and CEO
This article was originally published in Scrip
AVI BioPharma (US), a developer of RNA-based drugs, has appointed its chief financial officer, David Boyle, to the additional roles of interim president and chief executive officer. The appointment follows the resignation of Leslie Hudson. Anthony Chase, chairman of ChaseSource, has also joined AVI's board and its nominating and corporate governance committee, while Michael Forrest has stepped down. The company's board is now made up of seven directors, all of whom are independent.